ZA201407726B - Pharmaceutical compositions for combination therapy - Google Patents
Pharmaceutical compositions for combination therapyInfo
- Publication number
- ZA201407726B ZA201407726B ZA2014/07726A ZA201407726A ZA201407726B ZA 201407726 B ZA201407726 B ZA 201407726B ZA 2014/07726 A ZA2014/07726 A ZA 2014/07726A ZA 201407726 A ZA201407726 A ZA 201407726A ZA 201407726 B ZA201407726 B ZA 201407726B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical compositions
- combination therapy
- therapy
- combination
- pharmaceutical
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620203P | 2012-04-04 | 2012-04-04 | |
| US201261625192P | 2012-04-17 | 2012-04-17 | |
| US201361783730P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/035124 WO2013152105A1 (en) | 2012-04-04 | 2013-04-03 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201407726B true ZA201407726B (en) | 2016-05-25 |
Family
ID=49292803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/07726A ZA201407726B (en) | 2012-04-04 | 2014-10-23 | Pharmaceutical compositions for combination therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20130267552A1 (enExample) |
| EP (1) | EP2844346B1 (enExample) |
| JP (1) | JP6177875B2 (enExample) |
| KR (1) | KR20150013476A (enExample) |
| CN (1) | CN104470585A (enExample) |
| AU (1) | AU2013243461A1 (enExample) |
| BR (1) | BR112014024672A8 (enExample) |
| CA (1) | CA2869145A1 (enExample) |
| EA (1) | EA027748B1 (enExample) |
| ES (1) | ES2776678T3 (enExample) |
| HK (1) | HK1206297A1 (enExample) |
| IL (1) | IL234831B (enExample) |
| MX (1) | MX2014011971A (enExample) |
| NZ (1) | NZ630560A (enExample) |
| WO (1) | WO2013152105A1 (enExample) |
| ZA (1) | ZA201407726B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| WO2008127188A1 (en) * | 2007-04-12 | 2008-10-23 | Allbay Ab | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CA2847736A1 (en) | 2011-09-07 | 2013-03-14 | IVAX International GmbH | A new polymorphic form of pridopidine hydrochloride |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| SG11201509729YA (en) | 2013-06-21 | 2015-12-30 | Teva Pharmaceuticals Int Gmbh | Use of high dose pridopidine for treating huntington's disease |
| EA201691454A1 (ru) | 2014-01-22 | 2017-01-30 | Тева Фармасьютикалз Интернэшнл Гмбх | Композиции придопидина модифицированного высвобождения |
| CN106456651A (zh) * | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 以高用量含有四环性化合物的制剂 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| MX378579B (es) | 2015-02-25 | 2025-03-11 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| DK3419622T3 (da) | 2016-02-24 | 2024-06-03 | Prilenia Neurotherapeutics Ltd | Behandling af neurodegenerativ øjensygdom med pridopidin |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| PL4005570T3 (pl) | 2016-09-16 | 2024-09-23 | Prilenia Neurotherapeutics Ltd. | Pridopidyna do zastosowania w leczeniu zespołu retta |
| PL3570940T3 (pl) | 2017-01-20 | 2024-06-17 | Prilenia Neurotherapeutics Ltd. | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x |
| US11253594B2 (en) | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
| US11191758B2 (en) | 2017-07-20 | 2021-12-07 | Neurolixis | Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors |
| EP4620471A3 (en) | 2017-08-14 | 2025-11-26 | Prilenia Neurotherapeutics Ltd. | Treating amyotrophic lateral sclerosis with pridopidine |
| EA202090542A1 (ru) | 2017-08-30 | 2020-06-08 | Приления Ньюротерапьютикс Лтд. | Высококонцентрированные лекарственные формы придопидина |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| WO2020110128A1 (en) * | 2018-11-29 | 2020-06-04 | Prilenia Neurotherapeutics Ltd. | Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia |
| EP3678664A1 (en) * | 2017-09-08 | 2020-07-15 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| WO2019141708A1 (de) * | 2018-01-17 | 2019-07-25 | Hirschmann Car Communication Gmbh | Ein von einem empfangssystem abgesetztes lte-modul |
| AU2019261403B2 (en) | 2018-04-25 | 2025-05-15 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| WO2020161707A1 (en) | 2019-02-04 | 2020-08-13 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism |
| AU2021266476B2 (en) * | 2020-05-04 | 2024-10-10 | Prilenia Neurotherapeutics Ltd. | Treatment of viral infection, disease or disorder using a selective S1R agonist |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB850662A (en) | 1956-10-22 | 1960-10-05 | Parke Davis & Co | Substituted piperazines and processes for their production |
| BE662455A (enExample) | 1964-04-14 | |||
| GB1060160A (en) | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ZA7546B (en) | 1974-01-21 | 1976-08-25 | Parke Davis & Co | New antibacterial amide compounds and methods for their production |
| US4048314A (en) | 1974-12-17 | 1977-09-13 | Delmar Chemicals Limited | Morpholino containing 4-arylpiperidine derivatives |
| US4202898A (en) | 1978-06-05 | 1980-05-13 | Synthelabo | Method of treating anxiety and depression |
| US4267328A (en) | 1978-08-01 | 1981-05-12 | Synthelabo | 1-Phenylpiperazines |
| US4333942A (en) | 1979-08-03 | 1982-06-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Anti-depressant and analgesic 4-phenoxypiperidines |
| US4518712A (en) | 1980-06-30 | 1985-05-21 | Taiho Pharmaceutical Company Limited | Piperazine derivative and analgesic composition containing the same |
| GB2083476B (en) | 1980-09-12 | 1984-02-08 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| FR2501506A1 (fr) | 1981-03-11 | 1982-09-17 | Sanofi Sa | Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine |
| US4415736A (en) | 1981-12-28 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Certain tetrahydropyridine intermediates |
| US4485109A (en) | 1982-05-07 | 1984-11-27 | E. I. Du Pont De Nemours And Company | 4-Aryl-4-piperidinecarbinols |
| EP0094159B1 (en) | 1982-05-10 | 1990-03-14 | Takeda Chemical Industries, Ltd. | Dihydropyridine derivatives, their production and use |
| US4504660A (en) | 1982-07-06 | 1985-03-12 | American Home Products Corporation | Process for the production of 2,6-diaminobenzonitrile derivatives |
| DE3306964A1 (de) | 1983-02-28 | 1984-09-06 | Boehringer Ingelheim KG, 6507 Ingelheim | Neues n-arylpiperazin und verfahren zu seiner herstellung |
| HU198454B (en) | 1987-12-14 | 1989-10-30 | Richter Gedeon Vegyeszet | Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds |
| FR2639226B1 (fr) | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| DK0641320T3 (da) | 1991-04-17 | 2001-08-20 | Upjohn Co | Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister |
| PT100639A (pt) | 1991-06-27 | 1993-09-30 | Univ Virginia Commonwealth | Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina |
| NZ240863A (en) | 1991-09-11 | 1995-04-27 | Mcneilab Inc | Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof |
| GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| ES2162792T3 (es) | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d. |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| IL112099A (en) | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| IL114027A (en) | 1994-06-08 | 1999-11-30 | Lundbeck & Co As H | 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them |
| AU6470096A (en) | 1995-07-19 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused triazole compounds |
| ZA9610745B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ES2225979T3 (es) | 1996-07-22 | 2005-03-16 | Daiichi Suntory Pharma Co., Ltd. | Derivados de arilpiperidinol y de arilpiperidina y farmacos que los contienen. |
| US5892041A (en) | 1996-08-12 | 1999-04-06 | Neurogen Corporation | Fused indolecarboxamides: dopamine receptor subtype specific ligands |
| DE19637237A1 (de) | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
| US6159979A (en) | 1997-04-18 | 2000-12-12 | Smithkline Beecham P.L.C. | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity |
| KR100543614B1 (ko) | 1997-06-10 | 2006-01-20 | 신톤 비.브이. | 4-페닐피페리딘 화합물 |
| SE9702716D0 (sv) | 1997-07-15 | 1997-07-15 | Ross Nicholas Waters | Substituted phenylazacycloalkanes in the treatment of cognitive disorders |
| CA2267315C (en) * | 1997-08-07 | 2008-01-08 | Fujimoto Co., Ltd. | Ethylamine derivatives |
| US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
| AU757870B2 (en) | 1998-11-23 | 2003-03-06 | Sepracor, Inc. | Pharmaceutical compositions containing olanzapine-N-oxide |
| DE60025604T2 (de) | 1999-06-22 | 2006-07-27 | Neurosearch A/S | Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen |
| AU6386700A (en) | 1999-07-30 | 2001-02-19 | University Of Kentucky Research Foundation, The | Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| AU2001280599A1 (en) | 2000-07-15 | 2002-01-30 | Smith Kline Beecham Corporation | Compounds and methods |
| CA2432985A1 (en) | 2001-01-23 | 2002-08-01 | Vincent Mancuso | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| SE0200301D0 (sv) | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
| US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| KR101245075B1 (ko) | 2004-06-08 | 2013-03-18 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진 |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| EP2204363A1 (en) | 2004-06-08 | 2010-07-07 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission |
| US7884104B2 (en) | 2004-10-01 | 2011-02-08 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| WO2006040155A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| CA2584833A1 (en) | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-sulfonylphenyl)-piperidines |
| WO2007023141A1 (en) | 2005-08-22 | 2007-03-01 | Solvay Pharmaceuticals B.V. | N-oxides as prodrugs of piperazine & piperidine derivatives |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| WO2007065655A1 (en) | 2005-12-07 | 2007-06-14 | Neurosearch Sweden Ab | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
| EP2024363B1 (en) | 2006-05-02 | 2012-08-01 | Abbott Healthcare Products B.V. | N-oxides of pyridylmethylpiperazine and -piperidine derivatives |
| CA2651152A1 (en) | 2006-05-05 | 2007-11-15 | Astex Therapeutics Limited | 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer |
| EP1961742A1 (en) | 2007-02-22 | 2008-08-27 | Novartis AG | compounds of formula (I) as serine protease inhibitors |
| WO2008112278A2 (en) * | 2007-03-12 | 2008-09-18 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
| WO2008127188A1 (en) | 2007-04-12 | 2008-10-23 | Allbay Ab | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| ES2528040T3 (es) | 2007-06-18 | 2015-02-03 | A.Carlsson Research Ab | Uso de estabilizadores de dopamina |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| CA2743717A1 (en) | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| CA2764387A1 (en) * | 2009-06-05 | 2010-12-09 | Link Medicine Corporation | Aminopyrrolidinone derivatives and uses thereof |
| WO2011014003A2 (en) | 2009-07-29 | 2011-02-03 | Green Cross Corporation | (+)-3-hydroxymorphinan derivatives as neuroprotectants |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| US20130203886A1 (en) | 2010-03-05 | 2013-08-08 | Nileshkumar Prakash Kukalyekar | Process for the production of an uhmwpe article |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| US20130216856A1 (en) | 2010-07-02 | 2013-08-22 | Marco Burtchen | Mechanical component and method of surface hardening |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| CA2847736A1 (en) | 2011-09-07 | 2013-03-14 | IVAX International GmbH | A new polymorphic form of pridopidine hydrochloride |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
-
2013
- 2013-04-03 JP JP2015504706A patent/JP6177875B2/ja active Active
- 2013-04-03 EA EA201491819A patent/EA027748B1/ru active IP Right Revival
- 2013-04-03 WO PCT/US2013/035124 patent/WO2013152105A1/en not_active Ceased
- 2013-04-03 KR KR1020147030277A patent/KR20150013476A/ko not_active Withdrawn
- 2013-04-03 EP EP13772325.0A patent/EP2844346B1/en active Active
- 2013-04-03 BR BR112014024672A patent/BR112014024672A8/pt active Search and Examination
- 2013-04-03 ES ES13772325T patent/ES2776678T3/es active Active
- 2013-04-03 CA CA 2869145 patent/CA2869145A1/en not_active Abandoned
- 2013-04-03 MX MX2014011971A patent/MX2014011971A/es unknown
- 2013-04-03 CN CN201380018981.6A patent/CN104470585A/zh active Pending
- 2013-04-03 NZ NZ630560A patent/NZ630560A/en not_active IP Right Cessation
- 2013-04-03 US US13/856,254 patent/US20130267552A1/en not_active Abandoned
- 2013-04-03 HK HK15106790.2A patent/HK1206297A1/xx unknown
- 2013-04-03 AU AU2013243461A patent/AU2013243461A1/en not_active Abandoned
-
2014
- 2014-09-23 IL IL234831A patent/IL234831B/en active IP Right Grant
- 2014-10-23 ZA ZA2014/07726A patent/ZA201407726B/en unknown
-
2017
- 2017-06-02 US US15/612,779 patent/US20170266170A1/en not_active Abandoned
-
2018
- 2018-11-28 US US16/203,182 patent/US11207308B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014024672A2 (enExample) | 2017-06-20 |
| IL234831B (en) | 2020-10-29 |
| JP2015515475A (ja) | 2015-05-28 |
| US20170266170A1 (en) | 2017-09-21 |
| MX2014011971A (es) | 2015-01-16 |
| BR112014024672A8 (pt) | 2018-04-03 |
| HK1206297A1 (en) | 2016-01-08 |
| AU2013243461A1 (en) | 2014-11-06 |
| KR20150013476A (ko) | 2015-02-05 |
| NZ630560A (en) | 2016-11-25 |
| EA201491819A1 (ru) | 2015-04-30 |
| US20130267552A1 (en) | 2013-10-10 |
| CA2869145A1 (en) | 2013-10-10 |
| EP2844346A1 (en) | 2015-03-11 |
| EP2844346B1 (en) | 2020-01-01 |
| WO2013152105A1 (en) | 2013-10-10 |
| CN104470585A (zh) | 2015-03-25 |
| US11207308B2 (en) | 2021-12-28 |
| JP6177875B2 (ja) | 2017-08-09 |
| EA027748B1 (ru) | 2017-08-31 |
| US20200000785A1 (en) | 2020-01-02 |
| IL234831A0 (en) | 2014-12-31 |
| ES2776678T3 (es) | 2020-07-31 |
| EP2844346A4 (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201407726B (en) | Pharmaceutical compositions for combination therapy | |
| ZA201703992B (en) | Inhalable pharmaceutical compositions | |
| ZA201503594B (en) | Pharmaceutical compositions | |
| ZA201501930B (en) | Pharmaceutical composition | |
| EP2832730A4 (en) | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION | |
| IL266415A (en) | Innovative pharmaceutical composition | |
| ZA201409020B (en) | Pharmaceutical formulation | |
| SI2814473T1 (sl) | Farmacevtske sestave za kombinirano terapijo | |
| GB201205164D0 (en) | Pharmaceutical compounds | |
| GB201420971D0 (en) | Therapeutic composition | |
| IL217807A0 (en) | Therapeutic compositions | |
| ZA201502987B (en) | Pharmaceutical composition | |
| GB201202027D0 (en) | Pharmaceutical compounds | |
| GB201211153D0 (en) | Pharmaceutical compositions | |
| PT2814473T (pt) | Composições farmacêuticas para terapia de combinação | |
| IL238075A0 (en) | pharmaceutical preparations | |
| GB201219234D0 (en) | Pharmaceutical compositions | |
| GB201213303D0 (en) | Pharmaceutical compositions | |
| ZA201400751B (en) | Pharmaceutical composition | |
| GB201204810D0 (en) | Pharmaceutical compositions | |
| GB201221130D0 (en) | New pharmaceutical composition | |
| GB201207628D0 (en) | New pharmaceutical composition | |
| GB201207701D0 (en) | New pharmaceutical composition | |
| GB201211406D0 (en) | Pharmaceutical formulations | |
| GB201211403D0 (en) | Pharmaceutical formulations |